Oppenheimer Rates BridgeBio Oncology Therapeutics (BBOT) buy

Oppenheimer raised its rating on BBOT to buy, setting a $22 target, a 178.66% upside from the current price.

By EarningsIQ Research Desk · Published Jun 22, 2026, 2:01 PM EDT · Updated Jun 22, 2026, 9:06 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Oppenheimer rated BridgeBio Oncology Therapeutics, Inc. ($BBOT) "buy" with a $22 price target on June 22, 2026.

Since the rating, $BBOT is down 2.7% after 1 week, up 13.1% after 1 month and down 64.2% to date (from the $7.87 close on Jun 22, 2026).

BBOT BridgeBio Oncology Therapeutics, Inc.

$2.82 -77.05% year to date

Daily close · Oct 16, 2026

Key Points

Oppenheimer raised its rating on BBOT to buy with a $22 price target on June 22, 2026.
Oppenheimer's $22 price target implies 178.66% upside from BridgeBio Oncology Therapeutics, Inc.'s ($BBOT) current $7.89 share price.
Shares of BBOT traded at $7.89 on Monday, reflecting investor interest following the new rating.
Eventide Asset Management opened a new position in BBOT with 541,181 shares valued at $4.70 million.

Get $BBOT trade alerts by text

We text you when insiders, Congress or big funds trade $BBOT. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated BridgeBio Oncology Therapeutics, Inc. alert may contain errors. Disclosures

On June 22, 2026, Oppenheimer raised its rating on BBOT to a buy, setting a price target of $22. Analyst Mazahir Alimohamed made the call, highlighting confidence in the stock's potential. Shares of BBOT traded at $7.89 on Monday.

Analyst rating track record

Oppenheimer vs. the S&P 500

YTD return +50.42% hypothetical

All-time return +134.58% S&P 500 +30.17%

vs. S&P 500 +104.41% ahead of the index

Hypothetical returns from Oppenheimer's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in BBOT

Eventide Asset Management opened a new position in BBOT, acquiring 541,181 shares worth approximately $4.70 million. Avidity Partners Management also initiated a stake with 43,853 shares valued at $392,484. Accent Capital Management and Barclays PLC joined the list of new investors, adding 335 and 212 shares, valued at $2,998 and $1,897, respectively.

Analysts Set New Price Targets

On June 22, 2026, Oppenheimer assumed coverage of BBOT with a buy rating and a $22 price target. Earlier, on May 11, 2026, Canaccord Genuity initiated coverage with a buy rating and a $23 target. HC Wainwright & Co. maintained its buy rating with a $29 target on March 6, 2026. Other firms like Stifel and Raymond James have also recently initiated coverage with buy ratings and targets of $23 and $24, respectively.

Bottom Line

Oppenheimer's new buy rating and $22 target suggest optimism about BBOT's future prospects. Institutional interest, as seen with new positions from Eventide Asset Management and others, supports this view. Investors should remember that analysts' ratings and institutional moves are based on available data and projections, which can change over time.

12-month forecast